Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)

EURopean Trial Reduction Cardiac E, KM Fox, M Bertrand, R Ferrari, WJ Remme, ML Simoons, WJ Remme, M Simoons, JP Bassand, J Aldershvile, P Hildebrandt, M Bertrand, D Cokkinos, P Toutouzas, J Eha, L Erhardt, J Erikssen, P Grybauskas, U Kalnins, K KarschU Sechtem, M Keltai, W Klein, T Luscher, D Mulcahy, M Nieminen, A Oto, O Ozsaruhan, W Paulus, L Providencia, [No Value] Riecansky, W Ruzyllo, R Ferrari, U Santini, L Tavazzi, J Soler-Soler, P Widimsky, KM Fox, D Julian, H Dargie, G Murray, W Kubler, K Thygesen, D Duprez, G Steg, H Drexel, G Gombotz, W Klein, D Duprez, GH Heyndrickx, Lisa Legrand

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Background Treatment with angiotensin-converting-enzyme (ACE) inhibitors reduces the rate of cardiovascular events among patients with left-ventricular dysfunction and those at high risk of such events. We assessed whether the ACE inhibitor perindopril reduced cardiovascular risk in a low-risk population with stable coronary heart disease and no apparent heart failure.

Methods We recruited patients from October, 1997, to June, 2000. 13 655 patients were registered with previous myocardial infarction (64%), angiographic evidence of coronary artery disease (61%), coronary revascularisation (55%), or a positive stress test only (5%). After a run-in period of 4 weeks, in which all patients received perindopril, 12 218 patients were randomly assigned perindopril 8 mg once daily (n=6110), or matching placebo (n=6108). The mean follow-up was 4.2 years, and the primary endpoint was cardiovascular death, myocardial infarction, or cardiac arrest. Analysis was by intention to treat.

Findings Mean age of patients was 60 years (SD 9), 85% were male, 92% were taking platelet inhibitors, 62% beta blockers, and 58% lipid-lowering therapy. 603 (10%) placebo and 488 (8%) perindopril patients experienced the primary endpoint, which yields a 20% relative risk reduction (95% CI 9-29, p=0.0003) with perindopril. These benefits were consistent in all predefined subgroups and secondary endpoints. Perindopril was well tolerated.

Interpretation Among patients with stable coronary heart disease without apparent heart failure, perindopril can significantly improve outcome. About 50 patients need to be treated for a period of 4 years to prevent one major cardiovascular event. Treatment with perindopril, on top of other preventive medications, should be considered in all patients with coronary heart disease.

Original languageEnglish
Pages (from-to)782-788
Number of pages7
JournalThe Lancet
Volume362
Issue number9386
Publication statusPublished - 6 Sept 2003

Keywords / Materials (for Non-textual outputs)

  • CONVERTING-ENZYME-INHIBITOR
  • LEFT-VENTRICULAR DYSFUNCTION
  • MYOCARDIAL-INFARCTION
  • BLOOD-PRESSURE
  • HEART-FAILURE
  • EJECTION FRACTIONS
  • ENLARGEMENT TRIAL
  • ENDOTHELIAL-CELLS
  • HYPERTENSION
  • MORTALITY

Fingerprint

Dive into the research topics of 'Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)'. Together they form a unique fingerprint.

Cite this